NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE Drug Patent Profile

« Back to Dashboard

When do Norepinephrine Bitartrate In 5% Dextrose patents expire, and when can generic versions of Norepinephrine Bitartrate In 5% Dextrose launch?

Norepinephrine Bitartrate In 5% Dextrose is a drug marketed by Baxter Hlthcare Corp and Sagent and is included in three NDAs. There are three patents protecting this drug.

The generic ingredient in NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE is norepinephrine bitartrate. There is one drug master file entry for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the norepinephrine bitartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Norepinephrine Bitartrate In 5% Dextrose

A generic version of NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE was approved as norepinephrine bitartrate by MEITHEAL on March 3^rd, 2003.

Summary for NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE

US Patents:	3
Applicants:	2
NDAs:	3
Finished Product Suppliers / Packagers:	1
Clinical Trials:	12
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE
DailyMed Link:	NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE at DailyMed

Recent Clinical Trials for NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Siriraj Hospital	PHASE1
Visarat Palitnonkiat	PHASE1
Hassan II University	PHASE4

See all NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE clinical trials

Pharmacology for NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE

Drug Class

Catecholamine

US Patents and Regulatory Information for NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE

NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare Corp	NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	214313-001	Jan 15, 2021	AP	RX	Yes	Yes	12,097,170		Y
Baxter Hlthcare Corp	NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	214313-003	Nov 21, 2023	AP	RX	Yes	Yes	12,097,170		Y
Baxter Hlthcare Corp	NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	214313-002	Jan 15, 2021	AP	RX	Yes	Yes	12,097,170		Y
Sagent	NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	219692-001	Aug 11, 2025	AP	RX	No	No
Baxter Hlthcare Corp	NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	214313-001	Jan 15, 2021	AP	RX	Yes	Yes	12,290,494		Y
Baxter Hlthcare Corp	NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	214313-001	Jan 15, 2021	AP	RX	Yes	Yes	12,714,681		Y
Baxter Hlthcare Corp	NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	214313-002	Jan 15, 2021	AP	RX	Yes	Yes	12,290,494		Y

International Patents for NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE

See the table below for patents covering NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	3174640	SYSTEME DE RECIPIENT SCELLE CONDITIONNE DE STOCKAGE STABLE DE FORMULATION PHARMACEUTIQUE SENSIBLE A L'OXYGENE (PACKAGED, SEALED CONTAINER SYSTEM FOR STABLE STORAGE OF AN OXYGEN SENSITIVE PHARMACEUTICAL FORMULATION)
European Patent Office	4114336	SYSTÈME DE RÉCIPIENT SCELLÉ CONDITIONNÉ DE STOCKAGE STABLE DE FORMULATION PHARMACEUTIQUE SENSIBLE À L'OXYGÈNE (PACKAGED, SEALED CONTAINER SYSTEM FOR STABLE STORAGE OF AN OXYGEN SENSITIVE PHARMACEUTICAL FORMULATION)
World Intellectual Property Organization (WIPO)	2021178946
Canada	3174640
European Patent Office	4114336